Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
2(50%)
Results Posted
100%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
4
100%

Phase Distribution

0

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)

Detailed Status

Recruiting2
Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

recruiting250%
terminated125%
completed125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_2

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

NCT01804634
recruitingphase_2

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

NCT04232085
terminatedphase_2

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

NCT00505921
completedphase_2

Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma

NCT00834951

Clinical Trials (4)

Showing 4 of 4 trials
NCT01804634Phase 2

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Recruiting
NCT04232085Phase 2

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

Recruiting
NCT00505921Phase 2

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Terminated
NCT00834951Phase 2

Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma

Completed

All 4 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
4